This World Heart Day, 29 September, let’s spotlight a critical but often overlooked concern in healthcare — mitochondrial health. Healthy mitochondria are shown to be at the heart of maintaining optimal cardiovascular health.
While numerous studies have highlighted the impact of the COVID-19 pandemic on the cardiovascular system, it’s vital to recognise the broader health implications, such as brain fog and fatigue.[i] Shockingly, one in six Australians grapple with cardiovascular issues, imposing a staggering $5 billion burden on our healthcare system annually.[ii] World Heart Day serves as a timely reminder for us all to prioritise our heart health.
According to the eminent integrative cardiologist, Dr Ross Walker, maintaining high levels of ubiquinol—which naturally declines with age—is crucial for supporting heart function. Supported by over 90 clinical trials and studies, ubiquinol is gaining prominence as a scientifically-based, all-natural treatment option that healthcare practitioners can use to address multiple health conditions.
A 2020 study published in the American Journal of Cardiovascular Drugs unveiled promising results from ubiquinol supplementation in treating peripheral endothelial dysfunction—a condition linked to coronary artery disease and the development of acute coronary syndrome.[iii]
This World Heart Day, let’s make a commitment to not only raise awareness but also take proactive steps towards heart-healthy living. Let’s always remember: A healthy heart translates to a healthier life!
References:
[i] DePace NL, Colombo J. Long-COVID Syndrome and the Cardiovascular System: A Review of Neurocardiologic Effects on Multiple Systems. Curr Cardiol Rep 2022;24(11):1711-1726.
[ii] The Heart Foundation 2021. Key Statistics: Cardiovascular Disease [online] Available at: <https://www.heartfoundation.org.au/activities-finding-or-opinion/key-stats-cardiovascular-disease> [Accessed 15 September 2023].
[iii] Kawashima C, Matsuzawa Y, Konishi M, et al. Ubiquinol Improves Endothelial Function in Patients with Heart Failure with Reduced Ejection Fraction: A Single-Center, Randomized Double-Blind Placebo-Controlled Crossover Pilot Study. Am J Cardiovasc Drugs 2020;20(4):363-372.
Join us at FFWS 2025 Bangkok with Kaneka Ubiquinol™ to Discuss the Science Behind Healthy…
How Kaneka Ubiquinol™ can Mitigate the Effects of Stress and Poor Sleep The events that…
In an outstanding achievement, Kaneka Ubiquinol™, the global supplier of bioidentical Ubiquinol, has been awarded the Raw…
Kaneka Ubiquinol at the Complementary Medicines Australia Conference 2024 Today, Kaneka Ubiquinol was proud to…
Webinar with Dr Ross Walker, Integrative Cardiologist Our recent webinar, A Pharmacist’s Guide to Ubiquinol’s…
Kaneka Ubiquinol™ in New Zealand for Industry Innovation The Kaneka team was proud to attend…